Global Media Strategies -- Your Brand, Your Audience

Tranzyme Pharma announces approval of generic name “Ulimorelin” for TZP-101

January 27, 2010 By: NCTechNews Category: Biopharmaceutical

(Research Triangle Park, N.C.) Tranzyme Pharma has announced that the United States Adopted Name Council (USAN) has approved the generic name “ulimorelin” for Tranzyme’s novel, late-stage, prokinetic agent TZP-101. Ulimorelin, if approved, is expected to be a first-in-class drug for the treatment of gastrointestinal (GI) dysmotility indications in acute care (hospital-based) settings. Ulimorelin is a small molecule, intravenously-administered drug that targets the ghrelin receptor; ghrelin is responsible for energy homeostasis, appetite regulation and gastro-intestinal motility. The safety and pharmacokinetic profiles of ulimorelin have been extensively characterized in healthy subjects and patients across multiple dose levels, and the GI prokinetic properties of the compound have been well established in humans.

To date, ulimorelin has been successfully studied in two international Phase 2 trials, one for the management of postoperative ileus (POI) and a second for the treatment of acute gastroparesis, and has the potential to treat other conditions where a safe and effective GI prokinetic therapy is desired in acute care settings.

Helmut Thomas, PhD, DABT, Tranzyme’s Senior Vice President of Research and Preclinical Development, will present the case study, “Macrocycle-Based Drug Discovery: The Ulimorelin Story, at the upcoming Cambridge Healthtech Institute’s 17th International Molecular Medicine Tri-Conference being held February 3-5, 2010 in San Francisco, CA.

Tranzyme Pharma is a late stage biopharmaceutical company developing novel small molecule macrocyclic drugs for both acute care (hospital-based) and chronic indications with significant unmet medical need. The Company’s pipeline is derived from its proprietary MATCH™ technology and targets two validated GPCR drug targets, ghrelin and motilin. Ulimorelin is the first product discovered from MATCH™. In addition, Tranzyme is developing TZP-102, an oral ghrelin agonist which is in Phase 2 trials for the out-patient treatment of gastroparesis and other chronic GI and motility disorders, including GERD, functional dyspepsia, OBD and IBS-C.

For more information on Tranzyme, please visit: www.tranzyme.com.

Comments are closed.

← NCTechNews added to nationwide news network
Sensus exceeds five million smart grid endpoints →

  • Controlling Quality
    An RTP firm is gaining international notoriety as a leader in analytical instrumentation for the pharmaceutical and chemical manufacturing industries, sharing innovative solutions to evolving pharmaceutical and chemical manufacturing challenges, presenting on emerging multi-variant approaches to obtaining immediate, unambiguous results from drug product samples at a recent major international tradeshow.

    Portable Power
    Alternative energy solutions provider INI Power Systems, Inc. recently marked its ten-year anniversary by unveiling the innovative new Trinity™ series of portable alternative energy hybrid solutions at two major events catering to the defense and emergency first responder marketplaces, with attendees searching for reliable, flexible power systems with multiple applications.

    EV Innovation
    Morrisville-based green transportation pioneer Evatran™ recently hosted a demonstration of its Plugless Power™ hands-free electric vehicle (EV) charging system, showcasing cost savings and convenience of EV usage in residential, commercial and public applications.

    guide to success
    Entrepreneurs now have a workbook to guide them through successful implementation of business building blocks thanks to a new goal-setting toolkit for personal and professional success available at no charge from a Cary-based international strategic business consultant.

    Packaging Cures
    RTP-based advertising and branding firm The Marketing Machine helped overcome the issue of illiteracy among medical patients in Ghana, South Africa in designing packaging for the only manufacturer of anti-retroviral drugs in the region, creating individual icons and colors to help patients understand which drugs they needed, regardless of their ability to read.

    Broadband Stimulus
    Two grants funded by the American Recovery and Reinvestment Act are being used by MCNC to expand broadband connectivity and services throughout North Carolina and create more than 1,000 engineering and construction jobs, the organization said.

  • Recent Headlines

















free web site traffic and promotion